[DOI] [PMC free article] [PubMed] [Google Scholar] 250.Spanou C., Veskoukis A.S., Kerasioti T., Kontou M., Angelis A., Aligiannis N., Skaltsounis A.L., Kouretas D
In a multicenter, randomized, placebo-controlled dose-finding trial, cagrilintide at doses ranging from 0.3 to 4.5 mg weekly produced dose-dependent weight reductions, with the 4.5 mg dose achieving approximately 10.8% weight loss at 26 weeks compared to 3.0% with placebo
Tian, X
WHO Geneva
Buyers rebuilding supply chains should confirm current lead times and available lot quantities before committing to patient pipeline timelines
However, people with certain health conditions, such as kidney or heart problems, should consult a healthcare provider before treatment to ensure it is safe and appropriate